



Form PTO-1449				Attorney's Docket No. 39780-2630P1C21		Application Serial No. 09/978,423	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				Applicant(s) Ashkenazi <i>et al.</i>			
				Filing Date: October 16, 2001		Group Art Unit: 1648	
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
de	1.	08-20-1996	5,547,862	Meador <i>et al.</i>			
de	2.	11-14-2002	2002/0168713	Curtis, Rory A.J.			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
de	3.	Grifman, M. <i>et al.</i> , "Functional Redundancy of Acetylcholinesterase and Neuroligin in Mammalian Neuritogenesis," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp 13935-13940, 1998.					
de	4.	Sequence alignment of KIAA1260 protein of Nagase <i>et al.</i> with SEQ ID NO: 375. } Considered					
de	5.	Sequence alignment of SEQ ID NO: 2 of Curtis <i>et al.</i> with SEQ ID NO: 375. } Do not Print					

EXAMINER: <i>Emily Li</i>	DATE CONSIDERED: <i>1/24/06</i>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2156428 v1	